IMIC(SZ:000516) Sou Hu Cai Jing·2026-02-10 13:22Core Viewpoint - International Medical (000516) has shown a decline in revenue and profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 961 million yuan, a decrease of 18.95% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of February 10, 2026, the stock closed at 4.96 yuan, with an increase of 0.4% [1]. - The turnover rate was 1.55%, with a trading volume of 341,700 hands and a transaction amount of 169 million yuan [1]. - On February 10, the net inflow of main funds was 15.2399 million yuan, accounting for 8.99% of the total transaction amount [1]. - Retail investors experienced a net outflow of 280,100 yuan, representing 0.17% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions over the past 90 days is 5.5 yuan [3].